MacroGenics, Inc. (MGNX) News
Follow MacroGenics, Inc. (MGNX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MacroGenics Shares Fall 10% After Lorigerlimab Trial Data
Shares fell to $2.02 after trial data for the investigational cancer treatment showed high rates of severe side effects, including one patient death, and a high dropout rate.
EQUITY | Oct 26, 2026, 04:44 PM UTC
M
MacroGenics Reports 27% Response Rate in MGC026 Phase 1 Study
MacroGenics reported interim Phase 1 results showing a 27% response rate in heavily pretreated SCCHN patients and plans a front-line combination study with pembrolizumab.
EQUITY | Oct 23, 2026, 08:13 PM UTC
L
MacroGenics doses first patient in MGC030 Phase 1 study
The Phase 1 study is evaluating MGC030 in patients with advanced solid tumors.
EQUITY | Oct 15, 2026, 08:05 PM UTC
L
MacroGenics to participate in H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
MGNX - MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MGNX - MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 08:05 PM UTC
L
MacroGenics (MGNX) reports Q2 2026 financial results
MacroGenics (MGNX) reports its second-quarter 2026 financial results alongside updates on a streamlined operating model and a strengthened financial position.
EARNINGS | Aug 13, 2026, 08:09 PM UTC
L
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Tri
MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exerc
EQUITY | Aug 11, 2026, 08:22 PM UTC
M
MGNX Achieves $10 Million Milestone
MGNX achieves $10 million milestone after Gilead exercises option to license preclinical bispecific program
MNA | Aug 11, 2026, 08:08 PM UTC
M
MGNX Receives $24.5M Milestone
MacroGenics to receive $24.5M milestone from Sanofi following FDA approval of TZIELD expansion in type 1 diabetes
EARNINGS | Jun 22, 2026, 08:45 PM UTC
M
MGNX Receives Milestone
MacroGenics to receive milestone payment from Sanofi for recent TZIELD approval
EQUITY | Jun 22, 2026, 08:43 PM UTC